Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2010

View Archived Issues

Cediranib shows potential to treat epithelial ovarian, fallopian tube and peritoneal cancer

European Commission approves Pfizer's Revatio injection for pulmonary arterial hypertension

Ark Therapeutics files request with EMEA for re-examination of MAA for Cerepro

Boston Scientific initiates enrollment into postapproval study of Taxus Liberte stent

Data reported from three phase II studies of BIBW-2992 in metastatic breast cancer

PEG 15-20 to enter clinical trial after shown to protect rodent intestine from radiation

DAPH-12 and epigallocatechin gallate synergize to inhibit prion strains

8-Chloro-adenosine to be investigated in patients with breast cancer

BioInvent initiates treatment in phase I trial of BI-505 antibody for multiple myeloma

BioForm Medical to be acquired by Merz and renamed Merz Aesthetics

Dynavax Technologies acquires Symphony Dynamo

Dainippon Sumitomo submits NDA to FDA for lurasidone in schizophrenia

FDA grants priority review to InterMune's NDA for pirfenidone for idiopathic pulmonary fibrosis

Adventrx submits NDA to FDA for ANX-530

Anterogen begins phase I trial of ANT-SM in fecal incontinence

Novo Nordisk initiates phase I trial of oral insulin analogue NN-1952

First-in-man study of EMD-1214063 initiated in patients with solid tumors

FDA approves Takeda's sNDA for Velcade for first-line treatment of multiple myeloma

Janssen discloses novel HDAC inhibitors for cancer treatment

Swiss scientists present novel BB2 antagonists for cancer diagnosis and treatment

Dr. Reddy's Laboratories and Nordic Bioscience report results from phase III balaglitazone trial

MethylGene describes tyrosine kinase inhibitors for the treatment of proliferative diseases

Janssen presents protein kinase inhibitors for cancer therapy

Chinese scientists describe novel compounds for cancer treatment

NeoPharm files IND with FDA for phase I trial of IL-13-PE38QQR in idiopathic pulmonary fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...